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A B S T R A C T
Purpose
We investigated the correlation between the number of examined lymph nodes (ELNs) and correct
staging and long-term survival in non–small-cell lung cancer (NSCLC) by using large databases and
determined the minimal threshold for the ELN count.
Methods
Data from a Chinese multi-institutional registry and the US SEER database on stage I to IIIA resected
NSCLC (2001 to 2008) were analyzed for the relationship between the ELN count and stage migration
and overall survival (OS) by usingmultivariablemodels. The series of themean positive LNs, odds ratios
(ORs), and hazard ratios (HRs) were ﬁtted with a LOWESS smoother, and the structural break points
were determined by Chow test. The selected cut point was validated with the SEER 2009 cohort.
Results
Although the distribution of ELN count differed between the Chinese registry (n = 5,706) and the
SEER database (n = 38,806; median, 15 versus seven, respectively), both cohorts exhibited sig-
niﬁcantly proportional increases from N0 to N1 and N2 disease (SEER OR, 1.038; China OR, 1.012;
both P, .001) and serial improvements in OS (N0 disease: SEER HR, 0.986; China HR, 0.981; both
P , .001; N1 and N2 disease: SEER HR, 0.989; China HR, 0.984; both P , .001) as the ELN count
increased after controlling for confounders. Cut point analysis showed a threshold ELN count of 16 in
patients with declared node-negative disease, whichwere examined in the derivation cohorts (SEER
2001 to 2008 HR, 0.830; China HR, 0.738) and validated in the SEER 2009 cohort (HR, 0.837).
Conclusion
Agreater number of ELNs is associatedwithmore-accurate node staging and better long-term survival
of resected NSCLC. We recommend 16 ELNs as the cut point for evaluating the quality of LN ex-
amination or prognostic stratiﬁcation postoperatively for patientswith declared node-negative disease.
J Clin Oncol 35:1162-1170. © 2016 by American Society of Clinical Oncology. Licensed under the
Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
INTRODUCTION
Lung cancer is the leading cause of cancer-related
mortality worldwide, with approximately 85%
of patients having non–small-cell lung cancer
(NSCLC).1 For early-stage resectable NSCLC,
radical surgical resection remains the standard of
care. However, the postresection 5-year survival
rate is only 50% to 60%.2
Patients with positive lymph node (LN)
metastasis have a higher risk of disease recurrence;
thus, LN involvement is one of the most important
determinants for both prognosis and decisions
about treatment strategy in patients with resectable
NSCLC. LN sampling or dissection plays an im-
portant role in precise nodal staging by identifying
LN involvement and determining the extent of
disease and in the therapeutic effect of potential LN
metastatic lesion clearance. Precise staging is the
key to appropriate delivery of adjuvant therapies.
For example, adjuvant chemotherapy is recom-
mended for patients with NSCLC who have any
sign of LNmetastasis,3 and the beneﬁts of adjuvant
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chemotherapy in patients with node-positive NSCLC have been well
validated.4 In addition, the therapeutic effects of adjuvant therapy on
any unsuspected residual disease may also contribute to recurrence
risk reduction and improved survival.5
For many cancers, such as GI and breast cancers, the asso-
ciation between the greater number of examined LNs (ELNs) and
improved patient survival has been well studied. Therefore, Na-
tional Comprehensive Cancer Network (NCCN) guidelines rec-
ommend that the minimal number of LNs be removed or sampled
for adequate nodal staging.6-9 However, the current NCCN
guidelines for NSCLC recommend that surgeons sample only the
LN stations and state that one or more nodes be sampled from all
mediastinal stations (2R, 4R, 7, 8, and 9 for right-sided cancers; 4L,
5, 6, 7, 8, and 9 for left-sided cancers), according to the LN map
from the International Association for the Study of Lung Cancer.10
The minimum number of LNs that should be examined to ac-
curately stage or identify high-risk patients for disease recurrence
has not yet been well established or emphasized in NSCLC.
Some studies have shown a correlation between the number of
ELNs and long-term survival, but the results of these studies are
contradictory.11-18 Studies that were based on US SEER data
identiﬁed a positive correlation between the number of ELNs and
improved overall survival (OS),11-17 whereas another study that was
based on an Asian cohort suggested the reverse trend.18 Most of
these studies were ﬂawed because of the use of univariable analysis
that was biased by other signiﬁcant confounders. In addition, the
impact of the ELN number on stage correction in NSCLC has not
been studied. The diverse biologic behaviors that underlie various
histologic types may greatly inﬂuence the role of LN examination in
prognostication, but none of the studies examined the role of ELNs
separately according to histology. Moreover, the methods for
identifying the cut points were not sufﬁciently robust.11-18
To address these unresolved issues, we performed analyses of
two large databases that include various regions, ethnicities, and
clinical preferences, which may more accurately portray real-world
conditions to further conﬁrm the relationship between ELN and
long-term survival and stage migration. We used a multivariable
analysis to determine an optimal threshold for ELN count.
METHODS
Patient Population
Chinese multi-institutional registry. A multi-institutional registry of
consecutively collected data on patients with NSCLC who underwent surgical
resection between January 2001 and December 2008 at the departments of
thoracic surgery of seven institutions in the People’s Republic of China (The
First Afﬁliated Hospital of Guangzhou Medical University; Shanghai Pul-
monaryHospital of Tongji University; Shanghai ZhongshanHospital of Fudan
University; West China Hospital, Sichuan University; China and Japan
Friendship Hospital; Shenzhen People’s Hospital; and Cancer Center of Sun
Yat-Sen University) was used for the analyses. Data collection and processing
have been detailed previously.19 Brieﬂy, LNs were harvested during surgical
resection of NSCLC, and the tissue was examined postoperatively by pa-
thologists. The ELN counts in the registry were generated by adding the
surgeons’ intraoperative harvested LN count to the number of LNs identiﬁed
by pathologists postoperatively. Ethical approval was obtained from partici-
pating institutions through their respective institutional review boards. In
cases inwhich individual patient consent was not identiﬁed, the chairperson of
the ethics committee waived the need for patient consent. Patients were staged
by using the seventh edition of the TNMclassiﬁcation. An independent cohort
that comprised consecutive patients with NSCLC who underwent radical
resection between August 2009 and December 2011 at The First Afﬁliated
Hospital of GuangzhouMedical University was also used for cutoff validation.
SEER Database. SEER is representative of the US population, with
patient-level data abstracted from 18 geographically diverse populations
that represent rural, urban, and regional populations. NSCLC cases be-
tween 2001 and 2008 (to match the time span of the Chinese cohort) in the
SEER public access database and their corresponding details were retrieved
with the use of SEER*Stat version 8.1.5 software. Patients were uniformly
reviewed and staged according to the seventh edition of the TNM clas-
siﬁcation. An independent cohort of cases from 2009 was also retrieved for
cutoff validation.
Patient Selection
Patients who underwent surgical resection for ﬁrst primary NSCLC
with at least one examined LN were eligible. Patients with missing values
on ELN count and clinical features were excluded. Patients with stage IIIB
or IV disease were not eligible because surgery is not the standard of care.
ELN count was collected from database records.
Statistical Analyses
Multivariable regression analyses. We used the x2 test20 to compare
differences between categorical variables and t test21 for continuous
variables. The Cox proportional hazards regression model22 was used to
determine the effect of ELN number on OS and to visualize the survival
curves, which were adjusted for other signiﬁcant prognostic factors. On the
basis of the assumption that more ELNs present a greater opportunity to
identify positive LNs, stage migration was assessed by correlating the ELN
number and the proportion of each node stage category (node negative
versus node positive) by using a binary logistic regression model23 after
adjusting for other potential confounders associated with ELN number or
node stage before or during surgery. All calculations were performed with
SPSS version 17.0 for Windows software (IBM Corporation, Chicago, IL).
Accuracy of the number of involved LNs. A mathematical model of the
number of nodes examined was created by using hypergeometric distri-
bution and Bayes theorem in accordance with the procedures previously
described by Iyer et al.24 The resulting model was used to estimate the
accuracy of the reported number of positive nodes, in particular, the
probability of having at least one undetected positive LN among patients
with node-negative disease with different observed sampling numbers.
Fitting of curves and determination of structural break points. The
curves of odds ratios (ORs; stage migration) and hazard ratios (HRs; OS) of
each ELN count compared with one ELN (as a reference) as well as the
curves of mean positive number and probability of undetected positive LNs
were ﬁtted by using a LOWESS smoother with a bandwidth of 2/3 (default)
by using R version 3.2.2 software (Bell Laboratories, Murray Hill, NJ;
https://cran.r-project.org/bin/windows/base/old/3.2.2).25 Structural break
points were then determined by Chow test with the use of SAS 9.3 software
(SAS Institute, Cary, NC).26 The break points were considered the
threshold of clinical impact. P, .05 was considered statistically signiﬁcant.
RESULTS
Patient Characteristics and Distribution of ELN Number
A total of 38,806 patients in the US SEER cohort and 5,705
patients in the Chinese cohort who met the eligibility criteria were
included in this study. The baseline characteristics of each cohort are
listed in Table 1. There were 1,897 deaths recorded (censored,
66.7%) during a median follow-up of 3.6 years in the Chinese
cohort, and 17,029 deaths were recorded (censored, 56.1%) during
amedian follow-up of 5.0 years in the SEER cohort. The distribution
jco.org © 2016 by American Society of Clinical Oncology 1163
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of ELN number (Fig 1) differed between the cohorts; the Chinese
cohort had a larger number of ELNs (median, 15; interquartile
range, 10 to 22) than the SEER cohort (median, 7; interquartile
range, 4 to 12). An independent cohort with eligible cases from the
SEER database in 2009 as well as another cohort from The First
Afﬁliated Hospital of Guangzhou Medical University between 2009
and 2011 were retrieved for validation of the cut point (Table 1).
Number of Examined LNs and Population Stage
Migration
The mean ELNs differed signiﬁcantly within subcategories of
T staging, N staging, histology, tumor location, and operation type
in both cohorts (data not shown). All these factors were included in
the regression model. Both cohorts showed a signiﬁcantly pro-
portional increase in N stage (from N0 to N1 and N2), with an
increasing ELN count after adjusting for histology, T stage, tumor
location, and operation type (SEER: OR, 1.038; 95% CI, 1.035 to
1.041; P , .001; China: OR, 1.012; 95% CI, 1.006 to 1.019;
P , .001; Table 2). With regard to the correlation between ex-
amined LNs and positive LNs identiﬁed, a greater ELN count was
associated with a greater number of positive LNs (linear regression,
R2 = 0.917; P , .001), particularly in patients with node-positive
disease (R2 = 0.915; P , .001).
The SEER cohort was also used to estimate the empirical
distributions of the number of positive LNs; these results were then
used to calculate the probabilities of having more positive nodes
than observed (Appendix Table A1, online only). Special attention
was paid to the probability of having at least one or more un-
detected positive nodes in patients who were considered to have
node-negative disease. As expected, a greater number of ELNs
correlated with a lower probability of stage migration.
Number of ELNs and OS
After controlling for other prognostic factors (sex, age, pa-
thology, Tstage, and operation type), a greater number of ELNs was
positively correlated with better OS among both patients with node-
negative (N0) disease (SEER: HR, 0.986; 95% CI, 0.983 to 0.989;
P, .001; China: HR, 0.981; 95%CI, 0.972 to 0.989; P, .001) and
patients with node-positive (N1 and N2) disease (SEER: HR, 0.989;
95% CI, 0.986 to 0.992; P, .001; China: HR, 0.984; 95% CI, 0.977
to 0.990; P , .001), with a similar reduction in risk of death risk
(Table 2). Of note, among patients with node-positive disease, the
ELN count remained signiﬁcant after adding the number of positive
LNs to the Cox proportional hazards regression model (SEER: HR,
0.978; 95% CI, 0.975 to 0.982; P, .001; China: HR, 0.984; 95% CI,
0.977 to 0.990; P , .001). A consistent trend was observed in
Table 1. Patient Characteristics
Cohort China Registry, No. (%)
SEER Database (2001-2008),
No. (%)
SEER Database (2009),
No. (%)
Single-Center Cohort (2009-2011),*
No. (%)
Total 5,705 (100) 38,806 (100) 5,068 (100) 680 (100)
Sex
Male 3,959 (69.4) 19,677 (50.7) 2,515 (49.6) 397 (58.3)
Female 1,746 (30.6) 19,129 (49.3) 2,553 (50.4) 283 (41.6)
Age, years
# 65 4,014 (70.4) 17,363 (44.7) 2,103 (41.5) 468 (68.7)
. 65 1,691 (29.6) 21,443 (55.3) 2,965 (58.5) 213 (31.3)
Histology
SCC 1,782 (31.2) 10,733 (27.7) 182 (3.6) 149 (21.9)
ADC 3,038 (53.3) 15,530 (40) 1,474 (29.1) 416 (61.1)
ADSC 294 (5.2) 1,105 (2.8) 2,439 (48.1) 18 (2.6)
Large-cell carcinoma 105 (1.8) 1,561 (4) 136 (2.7) 7 (1.0)
BAC 281 (4.9) 5,191 (13.4) 242 (4.8) 26 (3.8)
Other† 205 (3.6) 2,324 (6) 331 (6.5) 63 (9.3)
NSCLC (unspeciﬁed) NA 2,188 (5.6) 264 (5.2) NA
T stage
T1a 761 (13.3) 8,646 (22.3) 1,281 (25.3) 123 (18.1)
T1b 771 (13.5) 6,698 (17.3) 892 (17.6) 82 (12.1)
T2a 2,710 (47.5) 13,958 (36) 1,768 (34.9) 350 (51.5)
T2b 679 (11.9) 3,183 (8.2) 386 (7.6) 73 (10.7)
T3 685 (12) 4,516 (11.6) 590 (11.6) 45 (6.6)
T4 99 (1.7) 1,805 (4.7) 151 (3.0) 6 (0.9)
N stage
N0 3,389 (59.4) 28,117 (72.5) 3,787 (74.7) 410 (60.2)
N1 961 (16.8) 5,865 (15.1) 706 (13.9) 90 (13.2)
N2 1,355 (23.8) 4,824 (12.4) 575 (11.3) 150 (22.0)
Operation type
Lobectomy 5,039 (88.3) 32,208 (83) 4,242 (83.7) 599 (88.0)
Sublobectomy 287 (5) 3,672 (9.5) 522 (10.3) 66 (9.7)
Pneumonectomy 377 (6.6) 2,750 (7.1) 290 (5.7) 15 (2.2)
Median ELN count (IQR) 15 (10-22) 7 (4-12) 8 (5-13) 19 (12-26)
Abbreviations: ADC, adenocarcinoma; ASDC, adenosquamous carcinoma; BAC, bronchoalveolar carcinoma; ELN, examined lymph node; IQR, interquartile range; NA,
not available; NSCLC, non–small-cell lung cancer; SCC, squamous cell carcinoma.
*The First Afﬁliated Hospital of Guangzhou Medical University.
†Includes sarcoma, pleomorphic carcinoma, giant-cell carcinoma, carcinoid, and so forth.
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patients with N2 disease (SEER: HR, 0.993; 95% CI, 0.989 to 0.997;
P = .002; China: HR, 0.985; 95% CI, 0.977 to 0.993; P , .001).
Interaction Tests for Histologic Subgroups
By including the product of the value of histologic subgroup
and ELN count, we tested the subgroup differences among various
histologic types. In both regression models that included stage
migration and OS, no signiﬁcant subgroup difference was detected
(Table 2). In addition, when bronchoalveolar carcinoma (an entity
used in the pathologic classiﬁcation of NSCLC during the data
collection) and large-cell carcinoma (which was considered to be
less affected by ELN count) were grouped together as one category,
no subgroup differences between this combined category and the
combined category that comprised of remaining histologic types
were found except for OS in Chinese registry patients with node-
negative disease. These results did not support a separate study of
ELNs and OS correlation on the basis of histology.
Cut Point Analysis for Patients With Node-Negative
Disease and Validation
Figure 2 shows the ﬁtting curves and corresponding structural
break points for both the OR of stage migration and the HR of OS
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Fig 1. Distribution of the number of harvested lymph nodes in the China registry and the SEER database. ELN, examined lymph node.
Table 2. Number of Examined Lymph Nodes (as a continuous variable) and Stage Migration, OS, and Interaction Tests for Histology
Stage Migration OS (Node-Negative Disease) OS (Node-Positive Disease)
Histologic Subgroup or Event Sig. OR LL UL P* Sig. HR LL UL P* Sig. HR LL UL P*
SEER database
Overall , .001 1.038 1.035 1.041 , .001 0.986 0.983 0.989 , .001 0.989 0.986 0.992
SCC , .001 1.039 1.033 1.045 .706 , .001 0.984 0.979 0.989 .058 .001 0.990 0.985 0.996 .680
ADC , .001 1.039 1.033 1.044 , .001 0.984 0.978 0.989 , .001 0.987 0.982 0.992
ADSC , .001 1.052 1.035 1.070 .048 0.983 0.966 1.000 .153 1.009 0.997 1.022
Large-cell carcinoma , .001 1.035 1.020 1.050 .055 0.987 0.973 1.000 .096 0.988 0.975 1.002
BAC , .001 1.038 1.028 1.047 .002 0.985 0.975 0.994 .001 0.980 0.968 0.992
Other† , .001 1.039 1.024 1.053 .363 1.006 0.993 1.018 .214 0.989 0.973 1.006
No. regroup (SCC-ADC-ADSC-others) , .001 1.039 1.035 1.043 .731 , .001 0.986 0.983 0.989 .876 , .001 0.99 0.986 0.993 .213
No. regroup (large-cell carcinoma-BAC) , .001 1.037 1.029 1.045 , .001 0.985 0.978 0.993 , .001 0.99 0.986 0.993
China registry
Overall , .001 1.012 1.006 1.019 , .001 0.981 0.972 0.989 , .001 0.984 0.977 0.990
SCC .003 1.018 1.006 1.030 .305 , .001 0.973 0.958 0.988 .079 , .001 0.977 0.966 0.989 .676
ADC .647 1.003 0.992 1.013 .001 0.979 0.967 0.992 .038 0.990 0.981 0.999
ADSC .457 1.012 0.981 1.045 .069 0.963 0.925 1.003 .056 0.975 0.949 1.001
Large-cell carcinoma .925 0.997 0.944 1.054 .367 1.023 0.974 1.074 .004 0.917 0.865 0.973
BAC .270 1.019 0.986 1.053 .257 1.021 0.985 1.059 .428 0.985 0.948 1.023
Other† .354 1.017 0.981 1.054 .072 0.968 0.935 1.003 .333 0.985 0.956 1.015
No. regroup (SCC-ADC-ADSC-others) .013 1.009 1.002 1.017 .176 , .001 0.976 0.967 0.985 .002 , .001 0.984 0.978 0.991 .624
No. regroup (large-cell carcinoma-BAC) .064 1.025 0.999 1.053 .048 1.029 1.000 1.058 .041 0.969 0.940 0.999
Abbreviations: ADC, adenocarcinoma; ADSC, adenosquamous carcinoma; BAC, bronchoalveolar carcinoma; HR, hazard ratio; LL, lower limit of 95% CI; OR, odds ratio;
OS, overall survival; SCC, squamous cell carcinoma; Sig., signiﬁcance; UL, upper limit of 95% CI.
*Interaction test P value.
†Includes sarcoma, pleomorphic carcinoma, giant-cell carcinoma, carcinoid, and so forth.
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in node-negative disease. The structural break points of the esti-
mated probabilities of having positive nodes in patients with node-
negative disease and the mean positive LNs identiﬁed at each ELN
count were also determined (Appendix Fig A1, online only).
All the break points essentially were in agreement with one
another (varied from 12 to 18). Because survival is the most im-
portant issue, we selected the structural break point of survival as the
cut point. For generalizability and representativeness, we used
a cutoff of 16 ELNs, which was generated from the SEER database.
The cut point was ﬁrst examined in both the Chinese and the
SEER cohorts where it was derived. Survival analysis conﬁrmed
signiﬁcantly reduced all-cause mortality of patients with at least 16
LNs harvested in node-negative NSCLC (SEER 2001 to 2008: HR,
0.830; 95% CI, 0.779 to 0.885; P , .001; Chinese registry: HR,
0.738; 95% CI, 0.655 to 0.831; P , .001) after adjusting for other
prognostic factors (Fig 3). The cut point was then validated in the
independent SEER 2009 cohort (HR, 0.837; 95% CI, 0.704 to
0.994; P = .043). Another independent validation from our single
center (The First Afﬁliated Hospital of Guangzhou Medical Uni-
versity, 2009 to 2011) that used disease-free survival as a measurement
was also performed (HR, 0.681; 95% CI, 0.435 to 1.066; P = .093;
Appendix Fig A2, online only).
DISCUSSION
In the current study, the stage migration analyses suggested that
a larger number of LNs sampled was associated with a higher
proportion of more-advanced N stage cases in the entire pop-
ulation, after adjusting for other risk factors for LN involvement.
This associationwas conﬁrmed by the trend of the mean number of
positive LNs as well as the probability of accuracy of negative LNs
with the mathematical model that was based on Bayes theorem. As
illustrated, the examination of more LNs can reduce the risk of
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Fig 2. LOWESS smoother ﬁtting curves of stage migration and overall survival and determination of structural break points with use of the Chow test. The ﬁtting
bandwidth was 2/3. (A) and (B) Stagemigration was estimated by logistic regression after adjusting for T staging, N staging, histology, tumor location, and operation type in
both cohorts. (C) and (D) Overall survival was estimated by using the Cox proportional hazards regression model after adjusting for sex, age, T staging, histology, and
operation type. ELN, examined lymph node.
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undetected positive LNs, which may result in a more thorough
elimination of remnants and proper delivery of adjuvant che-
motherapy to improve long-term survival. Accordingly, all cohorts
exhibited consistent positive correlation between a greater number
of ELNs and better OS in NSCLC with both positive and negative
node status. With regard to histology, we found a highly signiﬁcant
positive correlation between ELN and OS in squamous cell car-
cinoma and adenocarcinoma; however, for other histologic types,
the correlation was less uniform across cohorts most likely as
a result of the paucity of cases or because the node status did not
affect prognosis and treatment. However, interaction tests revealed
still-insufﬁcient power to study these issues separately on the basis
of histology.
Several possible underlying reasons for the correlation be-
tween the number of ELNs and OS exist. First, patients with
declared node-negative disease and with fewer ELNs may include
some who actually have N1 or N2 disease. For patients with node-
positive disease, those with a greater number of sampled LNsmight
include some who have received proper delivery of adjuvant
chemotherapy as a result of the correct staging (eg, prevention of
patients with node-positive disease from receiving a node-negative
diagnosis), which would therefore improve OS. We also found
hints of the beneﬁts of clearance of a potential malignancy by
dissecting more LNs. A greater number of ELNs was associated
with improved survival in patients with resectable N2 disease
among whom no stage migration would occur (patients with N3
disease were excluded). In this case, a higher ELN count means
a smaller chance of undiscovered positive LNs (namely malignancy
remnants, the potential source of recurrence), which thus indicates
a more favorable outcome.
Another key issue is an adequate threshold of ELN count to
allow a conﬁdent postoperative claim of node-negative disease.
Patients with fewer ELNs than the threshold might have a higher
risk of residual positive LNs and poorer survival. So far, recom-
mendations on ELN count have not been made in the NCCN
guidelines for NSCLC, but some studies have attempted to de-
termine a benchmark, with suggestions ranging between 10 and
18 LNs for the disease overall.14,18,27-30 In the current study, we
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identiﬁed an optimal cutoff of 16 ELNs for node-negative NSCLC,
which was validated in all cohorts. Of note, a study of complete
hilar and mediastinal lymphadenectomy found that the mean total
number of harvested LNs was 17.4 6 7.3,31 which precisely agrees
with the cut point we found. The threshold could be considered
one of the reference indexes for deﬁning inadequate LN sampling.
We also observed that ELN count has a prognostic impact despite
the number of positive nodes among patients with node-positive
disease. However, ﬁnding more positive LNs would not change the
treatment strategy because adjuvant chemotherapy is given rou-
tinely to patients with node-positive disease who can tolerate it. We
believe that the positive LN ratio (positive LNs/ELNs) would be
a better prognostic stratiﬁcation tool for node-positive disease;
therefore, we did not develop a cut point for ELN count.
To our knowledge, this study is currently the largest on such
issues to use multicenter, real-world data sets with robust statistics.
We sought to emphasize two major points. First, ELN count is
associated with improved outcomes in NSCLC; therefore, surgeons
and pathologists should pursue a maximal effort to explore the
LNs. Second, an increasing need exists to set up a minimal number
or range for evaluating the completeness of LN sampling for
NSCLC. For example, the NCCN guidelines suggest that patients
with node-negative disease and high-risk features receive adjuvant
chemotherapy; one of these features is incomplete LN sampling.
The number of LNs harvested could be one of the evaluation
criteria. This study was based on real-world patient data; therefore,
the surgical procedures, assessments, and enumeration of LNs
varied among regions, surgeons, laboratories, and pathologists.
This variance places a greater emphasis on adequate LN sampling
and dissection by surgeons in clinical practice and on the careful
exploration of the pulmonary LNs.
This study is limited by its retrospective nature. We were not
able to investigate some other important points such as the re-
spective impact of the number of N1 and N2 station LNs. We were
unable to use uniform counting methods because of the population
study design. In addition, two possible biases could have resulted in
a miscount of LN number: underestimation as a result of the
difﬁculty in separating each LN in the dissected tissues and
overestimation because of fragmentation of nodal tissues during
the removal of LNs, which might limit the application of a cut
point. We conservatively suggest that only complete LNs be
counted if LN fragmentation exists.
In conclusion, a greater number of ELNs is associated with
more-accurate node staging and better long-term survival of
resected NSCLC. We recommend 16 ELNs as the cut point for the
evaluation of the quality of postoperative LN examination or
prognostic stratiﬁcation for patients with declared node-negative
disease.
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Fig 3. Stratiﬁcation of overall survival
among patients with node-negative non–
small-cell lung cancer at the cut point of the
number of harvested lymph nodes (16)
on the basis of multivariable adjustments
(other covariates were sex, age, T staging,
histology, and operation type). ELN, ex-
amined lymph node.
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Fig A1. (A) LOWESS smoother ﬁtting curves of estimated probabilities of undetected positive lymph nodes (LNs) in patients with declared node-negative disease.
(B) Mean number of positive LNs as well as determination of structural break points by Chow test (ﬁtting bandwidth = 2/3). ELN, examined lymph node.
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Table A1. Probability of Having M + 1 or More Positive Nodes Given the Observation of M-Positive Nodes in N-Resected Nodes (calculated on the basis of the SEER
cohort)
N, M 0 1 2 3 4 5 6 7 8 9 10
1 0.3965 0.9343 — — — — — — — — —
2 0.3861 0.9283 0.9906 — — — — — — — —
3 0.3762 0.9222 0.9891 0.9984 — — — — — — —
4 0.3668 0.9160 0.9875 0.9980 0.9998 — — — — — —
5 0.3578 0.9098 0.9857 0.9976 0.9997 0.9999 — — — — —
6 0.3491 0.9034 0.9838 0.9971 0.9996 0.9999 1 — — — —
7 0.3407 0.8969 0.9818 0.9965 0.9995 0.9999 1 1 — — —
8 0.3327 0.8903 0.9796 0.9959 0.9993 0.9999 1 1 1 — —
9 0.3249 0.8836 0.9773 0.9952 0.9992 0.9998 1 1 1 1 —
10 0.3174 0.8769 0.9749 0.9945 0.9990 0.9998 1 1 1 1 1
11 0.3101 0.8700 0.9723 0.9936 0.9988 0.9997 1 1 1 1 1
12 0.3031 0.8631 0.9695 0.9926 0.9986 0.9997 0.9999 1 1 1 1
13 0.2962 0.8561 0.9666 0.9916 0.9983 0.9996 0.9999 1 1 1 1
14 0.2896 0.8490 0.9636 0.9904 0.9980 0.9995 0.9999 1 1 1 1
15 0.2831 0.8419 0.9604 0.9892 0.9976 0.9994 0.9999 1 1 1 1
16 0.2768 0.8346 0.9571 0.9878 0.9972 0.9992 0.9999 1 1 1 1
17 0.2707 0.8273 0.9536 0.9863 0.9968 0.9991 0.9998 1 1 1 1
18 0.2647 0.8199 0.9500 0.9847 0.9963 0.9989 0.9998 1 1 1 1
19 0.2589 0.8125 0.9463 0.9829 0.9957 0.9987 0.9997 0.9999 1 1 1
20 0.2532 0.8050 0.9424 0.9811 0.9951 0.9985 0.9997 0.9999 1 1 1
21 0.2476 0.7974 0.9384 0.9790 0.9944 0.9982 0.9996 0.9999 1 1 1
22 0.2422 0.7897 0.9342 0.9769 0.9936 0.9979 0.9995 0.9999 1 1 1
23 0.2368 0.7819 0.9298 0.9745 0.9927 0.9975 0.9994 0.9999 1 1 1
24 0.2316 0.7741 0.9254 0.9721 0.9917 0.9971 0.9993 0.9998 0.9999 1 1
25 0.2265 0.7662 0.9208 0.9694 0.9907 0.9966 0.9992 0.9998 0.9999 1 1
26 0.2215 0.7582 0.9160 0.9666 0.9895 0.9961 0.9990 0.9998 0.9999 1 1
27 0.2166 0.7502 0.9111 0.9637 0.9882 0.9955 0.9989 0.9997 0.9999 1 1
28 0.2118 0.7420 0.9061 0.9606 0.9868 0.9948 0.9987 0.9996 0.9999 1 1
29 0.2071 0.7338 0.9009 0.9573 0.9853 0.9940 0.9984 0.9996 0.9998 0.9999 1
30 0.2025 0.7255 0.8955 0.9538 0.9836 0.9932 0.9982 0.9995 0.9998 0.9999 1
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Fig A2. Stratiﬁcation of disease-free survival among patients with node-negative
non–small-cell lung cancer at the cut point of the number of harvested lymph
nodes (16) on the basis of multivariable adjustments (other covariates: sex, age,
T staging, histology, and operation type) of the single-center cohort (The First
Afﬁliated Hospital of Guangzhou Medical University).
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